We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal appeals court affirmed the dismissal of a lawsuit brought by the nonprofit AIDS Healthcare Foundation (AHF) challenging Gilead’s patents on several of its HIV drugs. Read More
HHS Secretary Alex Azar offered more details on Monday of a plan that could expand Medicare’s ability to negotiate prices, implicitly responding to claims that the administration’s new drug pricing blueprint is too easy on drugmakers. Read More
Green was alleged to have acquired shares in Southwest for a nominal sum in exchange for a guaranteed “dividend” worth about $5,000 per month, as long as she referred a certain amount of urine drug screens. Read More
Sponsors of pediatric HIV drugs should conduct bioequivalence studies in adults and enroll clinical trial subjects in cohorts based on weight rather than age, according to new FDA draft guidance. Read More
In a long-anticipated speech on drug pricing, President Trump announced reforms that “will bring soaring drug prices back down to earth,” but he cited few specifics and appeared to back off from a campaign promise to fight for Medicare to directly negotiate prescription prices. Read More